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ABSTRACT: Morquio A syndrome (mucopolysaccharidosis IVA) is an autosomal recessive disorder that
results from deficient activity of the enzyme Nacetylgalactosamine-6-sulfatase (GALNS) due to alterations in the GALNS gene, which causes major skeletal
and connective tissue abnormalities and effects on multiple organ systems. The GALNS alterations associated with
Morquio A are numerous and heterogeneous, and new
alterations are continuously identified. To aid detection
and interpretation of GALNS alterations, from previously
published research, we provide a comprehensive and upto-date listing of 277 unique GALNS alterations associated
with Morquio A identified from 1,091 published GALNS
alleles. In agreement with previous findings, most reported
GALNS alterations are missense changes and even the
most frequent alterations are relatively uncommon. We
found that 48% of patients are assessed as homozygous
for a GALNS alteration, 39% are assessed as heterozygous for two identified GALNS alterations, and in 13%
of patients only one GALNS alteration is detected. We
report here the creation of a locus-specific database for
the GALNS gene (http://galns.mutdb.org/) that catalogs
all reported alterations in GALNS to date. We highlight
the challenges both in alteration detection and genotype–
phenotype interpretation caused in part by the heterogeneity of GALNS alterations and provide recommendations
for molecular testing of GALNS.
Hum Mutat 35:1271–1279, 2014. Published 2014 Wiley Periodicals, Inc.∗∗
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Introduction
Morquio A syndrome (mucopolysaccharidosis IVA, MPS IVA;
MIM #253000) is an autosomal recessive lysosomal storage disorder
Additional Supporting Information may be found in the online version of this article.
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caused by deficient activity of the enzyme N-acetylgalactosamine-6sulfatase (GALNS; also known as N-acetylgalactosamine-6-sulfate
sulfatase or galactosamine (N-acetyl)-6-sulfate sulfatase; MIM
#612222) due to mutations in the GALNS gene. Deficient GALNS
activity causes accumulation of the glycosaminoglycans (GAGs) keratan sulfate (KS) and chondroitin-6-sulfate (C6S) in multiple tissues, which leads to skeletal and connective tissue abnormalities
together with pulmonary limitations and cardiac pathology [Harmatz et al., 2013; Montaño et al., 2007; Yasuda et al., 2013]. Morquio
A is a rare disorder, with an estimated incidence ranging from one in
76,000 births in Northern Ireland to one in 640,000 births in Western Australia [Hendriksz et al., 2013a; Nelson, 1997; Nelson et al.,
2003]. The clinical presentation of Morquio A is characterized by
variable expressivity, but even patients with more attenuated forms
of Morquio A are significantly affected and suffer substantial disease
burden [Montaño et al., 2007; Montaño et al., 2008; Tomatsu et al.,
2011; Hendriksz et al., 2013a; Harmatz et al., 2013].
Clinical suspicion of Morquio A syndrome typically leads to
screening urine GAG analysis or screening enzyme activities in
dried blood spot samples, but the gold standard for diagnosis of
Morquio A is demonstrating deficient GALNS enzyme activity in
either leukocytes or fibroblasts together with wild-type activity of
appropriate control enzymes to confirm sample integrity and exclude other disorders that can reduce GALNS enzyme activity, such
as multiple sulfatase deficiency or mucolipidosis type II/III [Wood
et al., 2013]. Molecular analysis can confirm the Morquio A diagnosis and aid genetic counseling by detecting the causative alterations
in the GALNS gene [Tylee et al., 2013; Wood et al., 2013].
The GALNS gene is approximately 50 kb in length and contains
14 exons, producing a 2,339 base pair mRNA that encodes a 522amino acid protein (Fig. 1) [Tomatsu et al., 1991; Nakashima et al.,
1994]. The alterations in the GALNS gene associated with Morquio
A are numerous and heterogeneous and have been found throughout the coding sequence and flanking splice sites; as of 2005, 148
unique gene alterations were known [Tomatsu et al., 2005b] and
many more have since been reported. The most common GALNS
gene alterations are missense alterations [Tomatsu et al., 2005b;
Hendriksz et al., 2013a]. DNA methylation at CpG sites has been
detected in every exon but the first, and the inappropriate repair
of spontaneous deamination events is thought to lead to transition mutations at these sites [Tomatsu et al., 2004]. Multiple
introns contain Alu repetitive elements (http://genome.ucsc.edu/,
February 2009 Assembly)[Meyer et al., 2013], which can undergo
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Figure 1. GALNS Gene Structure: a view of most frequently reported alleles and reported large deletions/rearrangements. GALNS enzyme
primary active site residues (Rivera-Colon et al., 2012) are indicated (∗): p.Asp39, p.Asp40, p.Cys/dihydroxyalanine79, p.Arg83, p.Tyr108, p.Lys140,
p.His142, p.His236, p.Asp288, p.Asn289, and p.Lys310.

recombination and potentially lead to large deletions and/or rearrangements. Even the most commonly detected GALNS alleles are
relatively uncommon, although some alleles are far more prevalent
in certain regions or ethnic group subpopulations, possibly due to
founder effects in which one or a few GALNS gene alterations were
present in populations started by a small number of individuals
[Tomatsu et al., 2005b; Wood et al., 2013; Yamada et al., 1998; Kato
et al., 1997]. This heterogeneity can pose challenges for the interpretation of molecular testing results from patients with Morquio
A because detection of novel GALNS gene alterations of unknown
significance may occur relatively frequently.

Reported GALNS gene alterations associated with Morquio A
were classified by mutation type, in many cases reporting deduced
changes to the GALNS amino acid sequence: missense alterations,
including alterations in the initial GALNS ATG and nucleotide substitutions eliminating the GALNS stop codon; nonsense alterations;
“insertion and/or deletion” alterations; and “intronic” alterations,
nucleotide substitutions in an intron (insertion/deletions occurring
in introns are classified as “insertion and/or deletion”).

Methods

Alterations in the GALNS Gene from Patients with
Morquio A

We performed a literature search for GALNS gene alterations
reported from patients with Morquio A when at least one altered
GALNS allele was reported. GALNS gene alteration data were gathered from the primary reports. When the information was available,
the gene alterations were recorded as patient genotypes (i.e., the two
GALNS alleles reported from a patient); however, there were 81 instances where GALNS gene alterations were reported in tabular lists
without information about their occurrence in patients. Some older
reports of GALNS gene alterations were adjusted so that all DNA and
protein sequence numbering is based on the GALNS cDNA sequence
(GenBank entry NM 000512.4), and the DNA sequence position “1”
corresponds to the A of the initial ATG in the reference sequence. In
some cases, errors in original publications have been corrected based
on subsequent reports or author communications (Supp. Table S1).
Sequence variant descriptions follow recommendations of the Human Genome Variation Society [den Dunnen and Antonarakis,
2000]. Assessed patient GALNS genotypes, assessments of disease
state, and patient geographic/ethnic affiliations are as reported in
the referred original publications(s) of that gene alteration.
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Results and Discussion

The information presented here serves as an update and augmentation to a previous comprehensive summary of alterations in
the GALNS gene associated with Morquio A syndrome [Tomatsu
et al., 2005b]. In addition to the inclusion of patient data and gene
alterations published since 2005, the data were gathered in the context of patient genotypes (i.e., the two GALNS alleles reported from
a patient) when available because this allows additional analyses
not possible previously. Additionally, three new genotypes from patients with Morquio A were recently published [Lachman et al.,
2014], including a patient with the novel GALNS gene alterations
c.317A.G (p.Asn106Ser) and c.553delG (p.Glu185Argfs14). These
data have been added to Supp. Table S2 only and are not included
in this manuscript’s analyses. This Mutation Update is a retrospective analysis of alterations in the GALNS gene as reported in the
primary literature. However, the possibility exists that a GALNS alteration reported to be associated with Morquio A disease may not
be causative, and so caution is warranted in the interpretation of
rare GALNS alterations with unclear molecular consequences.

Figure 2. Population properties of published patients with Morquio A. A: A plurality of patients with Morquio A are reported to be homozygous
for a GALNS gene alteration. All Morquio A patients with GALNS gene alteration data presented as a genotype were divided into the following
categories: those assessed to be homozygous for a reported GALNS gene alteration, heterozygous for two reported GALNS gene alterations, or
only one mutated GALNS allele reported. B: Frequency of reported alleles in patients with Morquio A by mutation type. GALNS alleles reported
from patients with Morquio A (i.e., totaling all reports of a given gene alteration; n = 1091) are categorized by alteration type; missense alterations
are further divided between the three most frequently reported alterations in the GALNS gene (c.1156C>T [p.R386C; n = 55]; c.337A>T [p.I113F;
n = 52]; and c.901G>T [p.G301C; n = 45]) and all other missense alterations (n = 706). C: Most GALNS gene alterations are rare. All reported GALNS
alleles are categorized and graphed by how often they have been reported in patients with Morquio A. Gene alterations that have been reported
only once or twice (two left columns) are divided between those gene alterations reported in a single patient or two or more patients. Two of the
87 alterations in the GALNS gene only reported once are from one instance of a GALNS allele reported from a patient with Morquio A where two
missense alterations—with unknown individual association with disease—are present in cis [Morrone et al., 2014]. The most frequently reported
GALNS gene alterations are listed in columns in order of reported frequency, with the top listed gene alterations the most frequently reported
within that category.
Genotypes from Patients with Morquio A
In a retrospective analysis, we identified from the literature 541
published genotypes of patients with Morquio A syndrome for
which at least one alteration in the GALNS gene was reported (Supp.
Table S2). Of these 541 patients, 257 patients (48%) were assessed as
being homozygous for an identified GALNS gene alteration, 212 patients (39%) were assessed as being heterozygous for two identified
gene alterations, and 72 patients (13%) had an alteration in only a
single GALNS allele identified (Fig. 2A). Because parental genotyping (to confirm a patient’s assessed genotype) and/or analysis for
large deletions and other rearrangements are often not performed,
an unknown subset of the patients assessed as homozygous actually
may be heterozygous for the detected GALNS gene alteration and an
undetected gene alteration (see Clinical and Diagnostic Strategies).

GALNS Alteration Types and Frequencies
First, we examined distinct unique gene alterations in GALNS
regardless of how frequently they are reported, counting multiple

reports of the same gene alteration only once. The 541 patients with
Morquio A from whom information about GALNS homozygosity
or heterozygosity was reported and the 81 instances of GALNS alleles reported in tabular form (where homozygosity or heterozygosity
was not reported) together contain 277 distinct reported gene alterations. Counting multiple reports of the same mutation as one
distinct gene alteration, missense alterations are the most frequently
reported distinct alterations in GALNS from patients with Morquio
A: distinct missense alterations account for 185 (67%) of the 277
reported distinct gene alterations, in close agreement with other
published results [Tomatsu et al., 2005b; Hendriksz et al., 2013a].
The next most common detected gene alteration type is insertions
and/or deletions (47 out of 277 distinct gene alterations; 17%). Of
the 47 detected distinct insertions and/or deletions, 28 are predicted
to cause frameshifts, 11 are in-frame deletions or insertions, and
eight likely have more complex effects. Detected deletions, both
small and large, outnumber detected insertions 39 to 8. Few large
deletions or complex rearrangements have been reported to date,
possibly due to under-detection (see Clinical and Diagnostic Strategies). Intronic changes (excluding deletions and/or insertions, which
HUMAN MUTATION, Vol. 35, No. 11, 1271–1279, 2014
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are considered above) account for 24 of the 277 distinct gene alterations (9%); 22 of these gene alterations affect one of the –1, –2, +1,
or +2 nucleotides. Nonsense changes account for 21 of the 277 distinct gene alterations (8%) in GALNS reported from patients with
Morquio A.
Next, we examined the frequency at which alterations in the
GALNS gene were reported from patients with Morquio A and totaled all reports of the same GALNS allele (Supp. Table S3, Fig. 2B).
This is different from the above analysis of gene alterations types as
a function of the 277 distinct gene alterations. This analysis is performed with a different denominator unit, the number of GALNS
alleles. The 541 patients with Morquio A have 1,010 reported mutant
GALNS alleles and 72 instances in which the second mutant GALNS
allele was not identified. The 1010 reported GALNS alleles from
patient GALNS genotypes were combined with 81 alleles reported
in tabular form to yield 1,091 reported mutant GALNS alleles in
patients with Morquio A. Of the 1,091 detected alleles, 858 are missense alleles (79% of all alleles; Fig. 2B). Again, this analysis differs
from that of the previous paragraph: from patients with Morquio A,
missense mutations are both the most frequently reported distinct
alterations in the GALNS gene (67% of 277 distinct alterations) and
the most frequently reported alleles (79% of 1,091 detected GALNS
alleles). Of the 1,091 mutant GALNS alleles reported from patients,
the three most commonly reported alleles together represent only
152 of 1,091 reported alleles (14%; Fig. 2B), again demonstrating the
heterogeneity of alterations in the GALNS gene from patients with
Morquio A [Tomatsu et al., 2005b](Fig. 2C). The allele most frequently reported is the missense change c.1156C>T (p.Arg386Cys),
reported 55 times (55 of 1,091; 5%); the second most frequently
reported allele was the missense change c.337A>T (p.Ile113Phe),
reported 52 times (52 of 1,091; 5%); and the third most reported
allele was the missense change c.901G>T (p.Gly301Cys), reported
45 times (45 of 1,091; 4%). These same three alleles are the most
frequent both in this data set and in Tomatsu et al. (2005b), but
their relative frequency is reduced in this data set. Compared with
Tomatsu et al. (2005b), here c.1156C>T (p.Arg386Cys) is 5% of reported GALNS alleles but 8.9% previously; c.337A>T (p.Ile113Phe)
is 5% of reported alleles here but 5.7% previously; and c.901G>T
(p.Gly301Cys) is 4% of reported alleles here but 6.8% previously.
Notably, many GALNS alleles have only been reported in a single
patient: 42 GALNS gene alterations have only been reported in the
homozygous state from a single patient and 86 of 277 gene alterations
(31%) have only been reported once (Fig. 2C).

GALNS Alleles and Geography
Worldwide, the ten most frequently reported GALNS gene alterations from patients with Morquio A (Table 1) are c.1156C>T
(p.Arg386Cys; reported 55 times), c.337A>T (p.Ile113Phe; reported
52 times), c.901G>T (p.Gly301Cys; reported 45 times), c.120+1G>A
(reported 23 times), c.1171A>G (p.Met391Val; reported 22
times), c.935C>G (p.Thr312Ser; reported 22 times), c.871G>A
(p.Ala291Thr; reported 20 times), c.860C>T (p.Ser287Leu; reported 20 times), c.953T>G (p.Met318Arg; reported 19 times), and
c.757C>T (p.Arg253Trp; reported 18 times).
In addition to overall differences in the frequency that individual GALNS alleles are reported, there are differences in reported
allele frequencies in specific subpopulations, which makes some alleles more or less common than might be expected. This analysis
relied on information of patients’ countries, regions, or ethnicities
as provided by the references, which may not have been collected
in a consistent manner. However, it is relevant to consider both the
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Table 1. Ten Most Frequently Reported GALNS Alleles from Patients with Morquio A, by Reported Countries/Ethnicities

Allele
p.Arg386Cys
Spanish
Argentine
Chinese
Italian
Colombian
Polish
Turkish
Chilean
All other countries/ethnicities
p.Ile113Phe
Irish
British
British/Irish
All other countries/ethnicities
p.Gly301Cys
Colombian
Portuguese
Spanish
All other countries/ethnicities
c.120+1G>A
Tunisian
All other countries/ethnicities
p.Thr312Ser
Irish
British/Irish
All other countries/ethnicities
p.Met391Val
French Canadian
French
Canadian Caucasian
American caucasian, German
All other countries/ethnicities
p.Ala291Thr
Asian-multiethnic
British
Finnish
Pakistani
Chinese
Japanese
All other countries/ethnicities
p.Ser287Leu
Middle Eastern
Turkish
Spanish
Polish
Greek
Macedonian
Austrian
New Zealander
Irish/Italian/Polish
All other countries/ethnicities
p.Met318Arg
Chinese
Taiwanese
Other
South-East Asian
Japanese
p.Arg253Trp
Pakistani
All other countries/ethnicities

Number
detected

Percentage of
that allele’s
total

Percentage of
all detected
alleles

55
9
6
5
4
3
3
3
3
14
52
27
15
3
7
45
16
6
5
10
22
20
2
22
14
3
5
22
7
4
3
2
6
20
8
4
3
2
1
1
1
20
4
3
2
2
2
2
1
1
1
2
19
11
3
2
2
1
18
16
2

100
16
11
9
7
5
5
5
5
35
100
52
29
6
13
100
36
13
11
40
100
91
9
100
64
14
23
100
32
18
14
9
27
100
40
20
15
10
5
5
5
100
20
15
10
10
10
10
5
5
5
10
100
58
16
11
11
5
100
89
11

5.0
0.8
0.5
0.5
0.4
0.3
0.3
0.3
0.3
1.3
4.8
2.5
1.4
0.3
0.6
4.1
1.5
0.5
0.5
0.9
2.0
1.8
0.2
2.0
1.3
0.3
0.5
2.0
0.6
0.4
0.3
0.2
0.5
1.8
0.7
0.4
0.3
0.2
0.1
0.1
0.1
1.8
0.4
0.3
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.2
1.7
1.0
0.3
0.2
0.2
0.1
1.6
1.5
0.2

“All other countries/ethnicities” includes not given.

reported country/regional, and/or ethnic affiliations associated with
patients with Morquio A, because in aggregate they reveal substantial
differences in the frequency of different GALNS alleles in different
populations. For example, the splice site mutation c.120+1G>A is
the fourth most frequently reported GALNS gene alteration from
patients with Morquio A, but most reports are for patients from
Tunisia (Table 1). The missense alteration c.337A>T (p.Ile113Phe)
is the second most frequently reported GALNS gene alteration from
patients with Morquio A, but it is most frequently reported in patients from the British Isles (Table 1), and for Morquio A patients
identified as of “Irish” descent, c.337A>T (p.Ile113Phe) represents
43% of all reported GALNS gene alterations (Table 2). Other localities beyond those listed in Table 2 also have high reported rates
of individual alterations; for example, the gene alteration c.901G>T
(p.Gly301Cys) is 50% of all reported alleles from Colombian patients with Morquio A. The high frequency of a specific GALNS
gene alteration in some populations could be due to founder effects.

Genotype–Phenotype Correlation
Morquio A disease severity descriptions historically focused primarily on height and growth, which measure only a specific manifestation of a disease that affects multiple body systems with variable
expressivity [Harmatz et al., 2013; Montaño et al., 2007; Yasuda
et al., 2013]. Patients have physical limitations resulting from the
skeletal, connective tissue, respiratory, and cardiac manifestations
of Morquio A; endurance, mobility, and the ability to complete
everyday activities (e.g., clipping nails or brushing hair) are also
relevant measures of disease severity [Harmatz et al., 2013]. The
International Morquio A Registry documented the natural course
of Morquio A disease and showed that frequent surgical interventions are required by patients with Morquio A [Montaño et al.,
2007]. Clinical experience demonstrates that the attenuated nature
of the disease is subjective and likely underestimated when only
height/growth are considered as a measure of disease severity. A
pair of siblings with Morquio A seen in clinical practice illustrates
this: one sibling was very short but ambulatory and with minimal
medical problems; whereas, the other sibling was taller but could
not walk independently and had a history of surgeries related to
Morquio A (personal communication, P. Harmatz). As de novo
GALNS mutations are rare and these sibs are expected to have the
same gene alterations, other genetic factors and their individual
medical histories may also contribute to these differences. These
siblings illustrate that height or growth-based metrics alone may
not capture fully the effect of Morquio A on a patient.
The genotype–phenotype relationship of 148 Morquio A GALNS
gene alterations was previously assessed [Tomatsu et al., 2005b]:
(1) by the homozygosity of the gene alteration, (2) by the level of
residual activity of the GALNS enzyme based on in vitro expression
study, (3) based on predictions of the effect of the gene alteration
on the protein structure, and (4) in patients with attenuated phenotypes with an allele permitting residual enzyme activity, which
would be dominant over an allele permitting no activity. Tomatsu
et al. [2005b] found 31 gene alterations associated with an attenuated phenotype and 101 gene alterations associated with a severe
phenotype but also noted the challenges in associating GALNS genotypes with Morquio A phenotypes. Rivera-Colon et al. (2012) also
recently summarized GALNS gene alterations with associated disease severity, which, in the existing Morquio A literature, generally
refers to a growth rate phenotype.
In a retrospective analysis, we summarize the mutation types
found in patients with Morquio A assessed to be homozygous for a

Table 2. Ten Most Reported Country/Ethnic Affiliations, by Number of Reported GALNS Alleles from Patients with Morquio A

Reported
country/ethnicity
Chinese
p.Met318Arg
p.Gly340Asn
p.Leu366Pro
All other alleles
Japanese
p.Asn204Lys
Double gene deletion
p.His430GlnfsTer71
Double deletion
c.121–2A>G
All other alleles
Irish
p.Ile113Phe
p.Thr312Ser
All other alleles
British
p.Ile113Phe
p.Ala291Thr
All other alleles
Asian-multiethnic
p.Gly116Val
p.Ala291Thr
p.Pro151Leu
p.Ala392Val
p.Leu36Arg
p.Gly139Ser
All other alleles
Turkish
p.Glu112ArgfsTer15
p.Met494Val
p.Trp141Arg
p.Leu390Ter
p.His236ArgfsTer25
p.Arg386Cys
p.Ser287Leu
All other alleles
Middle Eastern
p.Arg94Cys
p.Gly201Glu
p.Ser287Leu
p.Trp159Cys
p.Asp233Asn
c.121-1G>A
All other alleles
Italian
p.Arg386Cys
p.Met1Val
p.Trp10Ter
p.Phe167Val
p.Pro125Leu
p.Ala107Thr
All other alleles
Brazilian
p.Ser341Arg
p.Gly116Ser
p.Val239Phe
p.Cys165Tyr
p.Asn164Thr
p.Ala203Val
p.Arg386Cys
p.Gly301Cys
p.Arg94Cys
p.Val16Glu
p.Leu307Pro
p.Glu51Lys
All other alleles

Alleles detected
(all alleles,
including
unidentified)

Percentage of
that country’s
total

Percentage of
all detected
alleles

93 (118)
11
9
7
66
52 (67)
8
8
5
5
4
22
60 (63)
27
14
19
52 (62)
15
4
33
58 (58)
12
8
7
6
6
4
15
49 (51)
8
4
4
4
4
3
3
19
47 (48)
6
6
4
4
4
4
19
45 (45)
4
8
4
4
3
3
19
37 (38)
5
4
4
4
3
3
2
2
2
2
2
2
2

100
12
10
8
71
100
15
15
10
1
8
42
100
45
23
32
100
29
8
63
100
21
14
12
10
10
7
26
100
1
8
8
8
8
6
6
39
100
13
13
9
9
9
9
40
100
9
18
9
9
7
7
42
100
14
11
11
11
8
8
5
5
5
5
5
5
5

8.5
1.0
0.8
0.6
6.0
4.8
0.7
0.7
0.5
0.5
0.4
2.0
5.5
2.5
1.3
1.7
4.8
1.4
0.4
3.0
5.3
1.1
0.7
0.6
0.5
0.5
0.4
1.4
4.7
0.7
0.4
0.4
0.4
0.4
0.3
0.3
1.9
4.4
0.5
0.5
0.4
0.4
0.4
0.4
1.8
4.1
0.4
0.7
0.4
0.4
0.3
0.3
1.7
3.5
0.5
0.4
0.4
0.4
0.3
0.3
0.2
0.2
0.2
0.2
0.2
0.2
0.3
(Continued)
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Table 2. Continued

Reported
country/ethnicity

Alleles detected
(all alleles,
including
unidentified)

Percentage of
that country’s
total

Percentage of
all detected
alleles

Spanish
p.Arg386Cys
p.Gly301Cys
Exon 5 skipping
p.Tyr254Cys
p.Ser287Leu
p.Gly139Ser
All other alleles

36 (36)
9
5
5
5
2
2
8

100
25
14
14
14
6
6
22

3.3
0.8
0.5
0.5
0.5
0.2
0.2
0.7

et al., 2005; Gieselmann et al., 1991; Thomas, 1994; Zlotogora and
Bach, 1983]. The International Morquio A Registry documented
the heterogeneity of Morquio A disease and reported that 68.4%
of patients in the registry had a severe growth-impacted phenotype
and that 25% had either a mild or attenuated growth phenotype
[Montaño et al., 2007]. The analysis here, performed on an independent data set and reporting assessed growth phenotype, also found a
similar proportion of growth-impacted severity phenotypes: of the
patients with Morquio A homozygous for a GALNS gene alteration,
77% (107 of 139) have a reported severe growth phenotype, 4% (6 of
139) have an intermediate growth phenotype, and 19% (26 of 139)
have a less severe growth phenotype. Missense alterations were the
most commonly reported gene alteration type from homozygous
patients across all growth phenotypes, in agreement with the high
frequency of missense alterations reported in patients with Morquio
A (Fig. 2B, Tomatsu et al. 2005b, Hendriksz et al., 2013a]. In addition to missense alterations, homozygous patients with the most
severe growth phenotypes had other GALNS gene alteration types,
including insertions and/or deletions, intronic alterations, and nonsense alterations. The missense alterations found in patients with
more severe growth phenotypes are likely to be more deleterious
alleles, with stronger possible effects on the GALNS enzyme (Supp.
Table S4). With one exception, homozygous patients with less severe growth phenotypes had missense alterations; one patient with
a less severe growth phenotype was reported to be homozygous for
the intronic alteration c.898+1G>C [Tomatsu et al., 2005b]. Overall,
these results are consistent with a previous independent analysis
that found that most GALNS gene alterations associated with a less
severe growth phenotype were missense alterations (Tomatsu et al.,
2005b].

Locus-Specific Database

Figure 3. Assessed growth phenotype severity of patients with
Morquio A, by GALNS gene alteration type. All patients assessed as homozygous for a GALNS gene alteration were grouped by their assessed
growth phenotype and then divided by alteration type. Assessments of
“attenuated,” “slowly progressing,” or “mild” growth phenotypes were
grouped with “less severe” (n = 26); assessments of “moderate” were
grouped with “intermediate” (n = 6); and assessments of “rapidly progressing” and “severe” were grouped with “most severe” (n = 107).
Graph labels show the numbers of each GALNS gene alteration type
reported.

GALNS gene alteration for each of the growth phenotype categories
and report that, as expected, gene alterations expected to severely
affect protein function, such as deletions and nonsense gene alterations, are more common in patients with the most severely impacted growth phenotypes (Fig. 3, Supp. Table S4). We limited our
analysis to patients reported to be homozygous for a GALNS gene
alteration to avoid the possibility of any interallelic interactions (for
examples from other disorders, see refs. Caciotti et al., 2003; Caciotti
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We have developed a Locus-Specific Database (LSDB) for the
GALNS gene and a Website (http://galns.mutdb.org/) that supports
browsing, searching, and sorting the database as well as submissions
of new variations. Currently, the database includes previously published variants reported as “pathogenic” as well as those extracted
from dbSNP [Sherry et al., 2001], SwissProt (UniProt Consortium,
2014), and Cosmic [Forbes et al., 2011]. BioMarin assisted in the collation of these mutations, but no mutations were from data collected
as part of any BioMarin-sponsored clinical trial. This is in part because most BioMarin studies did not collect molecular testing data
as part of uniform enrollment criteria and also because the scope
of this update is to report only on published Morquio A mutations.
We have converted all variants to the nomenclature recommended
by HGVS [den Dunnen and Antonarakis, 2000], mapped transcript
positions to the protein when the annotations were missing in the
original publication as well as from the protein to the transcript
when this annotation was missing (for variants present in SwissProt for example). We have also annotated variants as “reported
pathogenic” or “benign” when a gene alteration was defined as such
in a published article or as a “variant of unknown clinical significance” otherwise. We record additional curator comments about
each gene alteration in a free text format in the comment section,
which can include growth phenotype severity or other evidence of
pathogenicity.
For missense alterations, we provide a bioinformatics analysis via
MutPred [Li et al., 2009] and PolyPhen2 [Adzhubei et al., 2010]
prediction scores and associated classifications for research purposes to aid assessment as to whether an amino acid substitution
is potentially deleterious. These scores and classifications are for

research use only and are not intended for use in clinical diagnosis of
Morquio A. A MutPred score cutoff of 0.5 was used to classify variations as “predicted non-pathogenic” or “predicted pathogenic.” We
have also listed every missense allele with either a MutPred or a
PolyPhen2 score below 0.75 (Supp. Table S5). To aid in assessment
of these alleles, the number of alleles reported and an estimate of the
likelihood of a familial relationship between the reported patients is
also provided.
In addition, we provide a JMOL protein structure viewer
(Jmol: an open-source Java viewer for chemical structures in 3D.
http://www.jmol.org/, accessed February 2014) for visualization of
each gene alteration. All submissions will be carefully curated moving forward by our curation team. BioMarin has not and will not
curate the LSDB. All GALNS variants in the LSDB are available for
inclusion in other resources. This LSDB for GALNS gene alterations
will encourage reporting of detected GALNS variants and will be a
useful resource for the Morquio A community. Again, diagnosis of
Morquio A should be made clinically and via demonstration of an
enzyme defect in GALNS alongside other normal lysosomal enzyme
activities in the context of a consistent clinical picture [Wood et al.,
2013].

Future Prospects
Animal Models and Therapies
It is important to consider the use of GALNS molecular testing
in the context of both what is known about Morquio A syndrome
to date as well as in the context of Morquio A patient care. Much
of our understanding about inherited disorders benefits from understanding animal models. However, although there are multiple
mouse models carrying different mutations in the murine GALNS
homolog [Tomatsu et al., 2003; Tomatsu et al., 2005a; Tomatsu et al.,
2007; Tomatsu et al., 2008; Tomatsu et al., 2010], mouse and human
catabolism of KS differs and the murine model did not develop the
dysostosis phenotype of Morquio A [Tomatsu et al., 2010]. Despite
the lack of a strong mouse disease model, enzyme replacement of recombinant human GALNS for Morquio A was able to proceed into
clinical development, and recent clinical investigation has largely
been focused on the evaluation of enzyme replacement therapy in
Morquio A (Clinicaltrials.gov;[Hendriksz et al., 2013b]. Enzyme replacement therapy with elosulfase alfa (BioMarin Pharmaceutical
Inc.) is now approved by the United States Food and Drug Administration for use in patients with Morquio A.
Although in some cases hematopoietic stem cell transplantation
(HSCT) may play a role in other MPS disorders, there have been
relatively few reports of HSCT performed in patients with Morquio
A [Tomatsu et al., 2011; Valayannopoulos and Wijburg, 2011]. Additionally, chaperone therapies and other small molecule therapies,
possibly designed with the aid of the GALNS structure [RiveraColón et al., 2012], could potentially benefit patients with Morquio
A at some point in the future [Valayannopoulos and Wijburg, 2011],
but useful application of these therapies would likely depend on
accurate identification of the underlying molecular defect in patients with Morquio A, emphasizing the need for accurate molecular
testing.

Newborn Screening
Once a therapy for a disorder becomes available, integration of
newborn screening may be considered. GALNS molecular testing
may be an important confirming test in the context of newborn

screening. In the future it may be possible to routinely screen newborns for mucopolysaccharidoses disorders, including Morquio A,
by using a liquid chromatography tandem mass spectrometry (LC–
MS/MS) approach to detect reduced GALNS enzyme activity in
dried blood spot samples [Spacil et al., 2013]. As the mucopolysaccharidoses are relatively rare disorders that can be difficult to diagnosis [Cimaz et al., 2009], widespread screening would be of great
benefit. Additionally, the rapid proliferation and future clinical use
of next-generation sequencing technologies may increase identification of individuals early in life with biallelic missense variants in
GALNS prior to the development of a clear-cut clinical phenotype.
These efforts and increasingly widespread availability of cheaper sequencing technologies in the future may lead to opportunities for
earlier diagnosis of Morquio A patients; however, there are limitations to running molecular screening panels for the purpose of
diagnosis that are outside of the scope of this review. We would like
to re-emphasize that for Morquio A, and other similar monogenetic
metabolic disorders for which there may be substantial numbers
of “novel” or “private” gene alterations identified, enzyme activity
testing is the standard for diagnosis [Wood et al., 2013].

Biomarkers
Although we recorded reported growth phenotype in the LSDB,
we confirm, as previously reported in the last mutation update, that
assessing genotype–phenotype relationships in Morquio A remains
a challenge [Tomatsu et al., 2005b]. The heterogeneous alterations
in the GALNS gene cause a spectrum of Morquio A disease manifestations and existing metrics of disease state do not always capture
the full disease burden for patients [Harmatz et al., 2013; Montaño
et al., 2007; Yasuda et al., 2013]. Biomarkers are needed to better understand Morquio A disease burden, aid patient counseling and the
design of clinical evaluation plans. The levels of KS present in either
plasma or urine have both been proposed as possible biomarkers
for Morquio A disease severity [Dung et al., 2013; Harmatz et al.,
2013]. The usefulness of plasma KS level as a biomarker is limited
by the overlap between measurements from normal individuals and
Morquio A patients [Longdon and Pennock, 1979; Martell et al.,
2011; Zanetti et al., 2009]. Urinary KS levels from patients with
Morquio A negatively correlate with both growth rates and final
height and positively correlate with greater impairment in clinical tests of endurance/mobility and respiratory capacity [Northover
et al., 1996; Montaño et al., 2008; Harmatz et al., 2013]. Future study
into the relationship between possible biomarkers for Morquio A
disease burden in the context of genotype–phenotype relationship
could provide improved early diagnosis and/or improved clinical
management of Morquio A syndrome.

Clinical and Diagnostic Strategies
Molecular analysis of the GALNS gene plays an important supporting role in the diagnosis of Morquio A. The gold standard for
diagnosis of Morquio A is detection of deficient GALNS enzyme
activity together with the wild-type activity of appropriate control enzymes [Wood et al., 2013]; detection of alterations in both
GALNS alleles can confirm the diagnosis and aid genetic counseling.
Accurate diagnosis of patients with Morquio A can be challenging,
particularly for individuals with more slowly progressing disease,
which makes confirmation of disease diagnosis by molecular analysis valuable.
The proportion of patients with Morquio A assessed as being
homozygous for a GALNS gene alteration is substantial. Of the
HUMAN MUTATION, Vol. 35, No. 11, 1271–1279, 2014
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published genotypes from patients with Morquio A for whom at
least one GALNS gene alteration was identified, 48% (257 out of
541) are assessed as being homozygous. Given the large number of
alterations in the GALNS gene and that the three most frequently detected disease-associated alleles represent a total of 14% (152 out of
1,091) of all detected alleles, the 48% rate of assessed homozygosity
suggests that factors such as founder effects and consanguinity may
influence the high rate of assessed homozygous patient genotypes.
It is possible that uniparental isodisomy (UPD) may cause homozygosity for a GALNS alteration in a small subset of cases. Although
identification of these cases is important for genetic counseling, to
date only one example has been reported [Catarzi et al., 2012].
Potentially, the percentage of patients with Morquio A assessed as
being homozygous may be higher than the true frequency. In a subset of apparently homozygous patients, it is possible that deletions,
rearrangements, and point mutations that eliminate binding sites
for genotyping primers will cause allele dropout and a false assessment of apparent homozygosity. Of note, few large deletions have
been reported from patients with Morquio A. Without additional
deletion-duplication testing (by use of an appropriate technique
such as quantitative genomic PCR (QF-PCR)), any deletion not entirely contained within an individual PCR amplicon will likely be
missed by current sequencing approaches. Potentially, undetected
large deletions could both cause apparent homozygosity and may
contribute to the 13% of published patient genotypes for which only
one GALNS gene alteration is identified (Fig. 2A).
Routine parental genotyping is recommended in the Morquio A
diagnostic algorithm [Wood et al., 2013]; however, parental genotyping is not often performed and is even less frequently described
in the literature. Parental genotyping results can aid interpretation
of results from the patient and facilitate genetic counseling by allowing detection of situations in which the patient’s results alone
might lead to inaccurate conclusions being drawn; examples include
cases in which two detected gene alterations are in cis, homozygosity due to UPD [Catarzi et al., 2012], and cases of allele dropout
causing apparent homozygosity [Landsverk et al., 2012; Tylee et al.,
2013]. One center performing molecular testing for multiple different autosomal recessive disorders found that, after performing
parental testing on 75 patients initially assessed to be homozygous,
four patients were incorrectly assessed as homozygotes due to allele
dropout and two patients were genuinely homozygous but via UPD
[Landsverk et al., 2012]. However, circumstances will not always
allow for parental testing to be performed, particularly when it may
raise a question of paternity.
The numerous GALNS gene alterations associated with Morquio
A can make interpretation of molecular analysis results difficult. As
with other Mendelian disease genes, the detection of novel GALNS
alterations will occur relatively frequently. Additionally, there are
GALNS sequence variants in exons (Supp. Table S6) and introns
that have been reported without accompanying phenotypic information or a clear association with Morquio A. Although the functional consequences of some GALNS gene alterations can readily
be predicted, such as nonsense alterations or large deletions, predicting the consequences of novel missense alterations from the
sequence change alone can be difficult. The detection of a variant
multiple times in patients with Morquio A from independent families strongly supports linking a variant with Morquio A disease;
conversely, novel, difficult-to-interpret gene alterations (e.g., many
missense alterations) should be interpreted with caution and only
limited conclusions drawn [Morrone et al., 2014]. Consequently,
reporting detected GALNS alterations facilitates the differentiation
of disease-associated alleles from benign alterations and should be
encouraged.
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